Taxotere® (Docetaxel) plus Estramustine Confirmed Superior to Taxotere Alone for Hormone Refractory Prostate Cancer
A recent multi-center U.S. clinical trial has concluded that Taxotere and Estramustine improved survival of men with hormone refractory prostate cancer (HRPC) when compared to the standard regimen of Mitoxantrone and Prednisone.
In addition, a recent French trial reported that a regimen of Taxotere, Estramustine and Prednisone was also superior to a regimen of only Mitoxantrone plus Prednisone.
CONCLUSION: Adding Estramustine improves survival and should be the standard of care for HRPC.
Do not forget to discuss this with your doctor.
Joel T Nowak MA, MSW